Hubbry Logo
PyrosequencingPyrosequencingMain
Open search
Pyrosequencing
Community hub
Pyrosequencing
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Pyrosequencing
Pyrosequencing
Pyrosequencing
View on Wikipedia
from Wikipedia

Pyrosequencing is a method of DNA sequencing (determining the order of nucleotides in DNA) based on the "sequencing by synthesis" principle, in which the sequencing is performed by detecting the nucleotide incorporated by a DNA polymerase. Pyrosequencing relies on light detection based on a chain reaction when pyrophosphate is released, hence, the name given it.

Principles

[edit]

The principle of pyrosequencing was first described in 1993 by P. Nyrén, B. Pettersson, and M. Uhlen.[non-primary source needed][1] The technique combines solid phase sequencing, and use of streptavidin-coated magnetic beads, a recombinant DNA polymerase lacking 3´-to-5´exonuclease activity (proof-reading), and luminescence detection of inorganic pyrophosphate using the firefly luciferase enzyme.[non-primary source needed][2][3][clarification needed]

Specifically, a solution of three enzymes—DNA polymerase, ATP sulfurylase, and firefly luciferase—and a deoxyribonucleoside triphosphate (dNTP) are added to single stranded DNA to be sequenced, and the incorporation of nucleotide is followed, measuring the light emitted as a consequence of inorganic pyrophosphate production.[citation needed] The intensity of the light determines if 0, 1, or more nucleotides have been incorporated, thus showing how many complementary nucleotides are present on the template strand.[citation needed] The nucleotide mixture is removed before a next nucleotide mixture is added, and the process is repeated for each of the four nucleotides, until the DNA sequence of the single stranded template is determined.[citation needed]

A second solution-based method for pyrosequencing was described in 1998 by Mostafa Ronaghi, [Mathias Uhlen],[4] and Pål Nyren.[non-primary source needed][5] In this alternative method, an additional enzyme, apyrase, is introduced to remove nucleotides that are not incorporated by the DNA polymerase.[citation needed] This enables the enzyme mixture— DNA polymerase, luciferase, and apyrase—to be added when sequencing is initiated, and kept in the reaction solution throughout the procedure (thus enabling easier automation).[citation needed] An automated instrument based on this principle was introduced to the market the following year by the company Pyrosequencing.[citation needed]

A third variant, a microfluidic pyrosequencing method, was described in 2005 by an industrial research team led by Jonathan Rothberg, at the company 454 Life Sciences.[non-primary source needed][6] This alternative approach for pyrosequencing was based on the original principle of attaching the DNA to be sequenced to a solid support; Rothberg and co-workers demonstrated that sequencing could be performed in a highly parallel manner using a microfabrication and microarrays.[citation needed] This allowed high-throughput DNA sequencing, and an automated instrument was introduced to the market.[citation needed] This first next generation sequencing instrument initiated a new era in genomics research,[according to whom?] and to rapidly falling prices for DNA sequencing,[according to whom?] allowing affordable whole genome sequencing.[citation needed]

Procedure

[edit]
How Pyrosequencing Works
The chart shows how pyrosequencing works.

"Sequencing by synthesis" involves taking a single strand of the DNA to be sequenced and then synthesizing its complementary strand enzymatically. The pyrosequencing method is based on detecting the activity of DNA polymerase (a DNA synthesizing enzyme) with another chemoluminescent enzyme. Essentially, the method allows sequencing a single strand of DNA by synthesizing the complementary strand along it, one base pair at a time, and detecting which base was actually added at each step. The template DNA is immobile, and solutions of A, C, G, and T nucleotides are sequentially added and removed from the reaction. Light is produced only when the nucleotide solution complements the first unpaired base of the template. The sequence of solutions which produce chemiluminescent signals allows the determination of the sequence of the template.[7][better source needed][verification needed]

For the solution-based version of pyrosequencing, the single-strand DNA (ssDNA) template is hybridized to a sequencing primer and incubated with the enzymes DNA polymerase, ATP sulfurylase, luciferase and apyrase, and with the substrates adenosine 5´ phosphosulfate (APS) and luciferin.[7][verification needed]

  1. The addition of one of the four deoxynucleotide triphosphates initiates the second step; dNTPs)—dATPαS, which is not a substrate for a luciferase, is added instead of dATP to avoid noise. DNA polymerase incorporates the correct, complementary dNTPs onto the template. This incorporation releases pyrophosphate (PPi).[7][verification needed]
  1. ATP sulfurylase converts PPi to ATP in the presence of adenosine 5´ phosphosulfate. This ATP acts as a substrate for the luciferase-mediated conversion of luciferin to oxyluciferin that generates visible light in amounts that are proportional to the amount.[clarification needed] The light produced in the luciferase-catalyzed reaction is detected by a camera and analyzed in a program.[7][verification needed]
  1. Unincorporated nucleotides and ATP are degraded by the apyrase, and the reaction can restart with another nucleotide.[7][verification needed]

The process can be represented by the following equations:

  • PPi + APS → ATP + Sulfate (catalyzed by ATP-sulfurylase);
  • ATP + luciferin + O2 → AMP + PPi + oxyluciferin + CO2 + hv (catalyzed by luciferase);

where PPi is pyrophosphate, APS is adenosine 5-phosphosulfate, ATP is adenosine triphosphate, O2 is dioxygen, AMP is adenosine monophosphate, CO2 is carbon dioxide, and hv is light.[7][verification needed]

Limitations

[edit]

Currently, a limitation of the method is that the lengths of individual reads of DNA sequence are in the neighborhood of 300-500 nucleotides, shorter than the 800-1000 obtainable with chain termination methods (e.g. Sanger sequencing).[citation needed] This can make the process of genome assembly more difficult, particularly for sequences containing a large amount of repetitive DNA.[citation needed] Also, lack of a proof-reading activity[clarification needed] limits accuracy of this method.[citation needed]

Commercialization

[edit]

Pyrosequencing AB, a company based in Uppsala, Sweden, was founded with venture capital provided by HealthCap in order to commercialize machinery and reagents for sequencing short stretches of DNA using the pyrosequencing technique.[8][verification needed] Pyrosequencing AB was listed on the Stockholm Stock Exchange in 1999.[8][verification needed] When Pyrosequencing AB acquired Biotage LLC, a U.S.-based company, and other companies, in 2003, the company was renamed Biotage AB.[8] The pyrosequencing and other biomedical units of Biotage AB were sold to Qiagen in 2008.[8][verification needed] The pyrosequencing technology was licensed to 454 Life Sciences.[when?][citation needed] 454 developed an array-based pyrosequencing technology that emerged as a platform for large-scale DNA sequencing, including genome sequencing and metagenomics.[citation needed]

Roche acquired 454 Life Sciences,[when?][citation needed] and announced the discontinuation of the 454 sequencing platform in 2013.[9] The 454 sequencing platform was replaced, in part, by Illumina dye sequencing, and by Applied Biosystems sequencing products.[citation needed]

Further reading

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Pyrosequencing

View on Grokipedia
from Grokipedia
Pyrosequencing is a DNA sequencing technology that determines the order of nucleotides in a DNA strand through the sequencing-by-synthesis principle, detecting the release of inorganic pyrophosphate (PPi) during nucleotide incorporation by DNA polymerase in real time. The method employs a cascade of enzymatic reactions: ATP sulfurylase converts the released PPi into ATP using adenosine phosphosulfate (APS), which then drives the luciferase-mediated oxidation of luciferin to produce visible light; the intensity of this bioluminescent signal is proportional to the number of incorporated nucleotides, enabling quantitative sequence readout without electrophoresis or labeled primers. Initially developed for short-read applications, it facilitates accurate analysis of DNA sequences up to several hundred base pairs. The foundational concept of pyrosequencing emerged from earlier work on enzymatic detection of PPi release, with the initial solid-phase minisequencing approach described in 1993 for identifying single-base changes in PCR-amplified DNA templates. This was advanced in 1996 to enable real-time sequencing of nascent DNA strands using natural deoxynucleotides and apyrase for unincorporated nucleotide removal, followed by a 1998 refinement that improved incorporation efficiency and automation. Commercialization began in the late 1990s through Pyrosequencing AB (now part of QIAGEN), and it gained prominence with the 454 Life Sciences platform in 2005, which integrated emulsion PCR for clonal amplification and high-throughput processing, achieving up to 1 million reads per run by the early 2010s. Although largely superseded by newer next-generation sequencing technologies for long-read whole-genome analysis, pyrosequencing remains valued for its precision in targeted applications. Key strengths of pyrosequencing include its high accuracy for short sequences (error rates below 1% for reads under 100 ), quantitative detection of frequencies, and avoidance of PCR biases associated with . However, it struggles with homopolymer regions, where signal intensity may inaccurately reflect repeat lengths beyond six nucleotides, and its read lengths are limited compared to modern platforms. Notable applications encompass (SNP) genotyping, profiling via bisulfite treatment, microbial community analysis through 16S rRNA amplicon sequencing, and mutation detection in clinical diagnostics, such as identifying variants. Its legacy endures in fields requiring rapid, cost-effective quantification of sequence variants, contributing to advancements in genomics and .

History

Development and Invention

Pyrosequencing was invented in 1993 by Pål Nyrén, Bertil Pettersson, and Mathias Uhlén at the Royal Institute of Technology in , , as a real-time method that detects release during incorporation by . The core innovation built on Nyrén's earlier 1987 development of an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA) for monitoring polymerase activity, adapted here for sequencing applications. The foundational publication appeared that same year, introducing an enzymatic cascade involving ATP sulfurylase to convert released to ATP in the presence of adenosine 5'-phosphosulfate, followed by luciferase-mediated conversion to detectable light via . This luminometric approach enabled non-radioactive, electrophoresis-free detection of single-base extensions, marking a shift toward sequencing-by-synthesis principles. Early prototypes relied on solution-based assays, where unincorporated were removed manually through washing steps or by passing the reaction mixture through sequential chromatographic columns containing immobilized enzymes, avoiding the need for apyrase in the core reaction. These designs prioritized simplicity in quantification but required iterative separation to maintain sequencing synchrony. A key feature of the initial setups was the use of a biotin-streptavidin system for immobilizing biotinylated, single-stranded DNA templates onto streptavidin-coated magnetic beads, enabling efficient solid-phase minisequencing while preserving template accessibility for polymerase and primer annealing. This immobilization strategy facilitated repeated washing and reuse of the template, foundational to the method's practicality.

Key Milestones and Evolution

In 1996, Mostafa Ronaghi and colleagues advanced pyrosequencing by developing a real-time sequencing method that detected release during , using a modified (dATPαS) to improve signal detection and allowing sequencing of up to 15 bases from PCR products. In 1998, a significant advancement in pyrosequencing came with the introduction of the apyrase by Mostafa Ronaghi and colleagues, which enabled the cyclic dispensing of all four deoxynucleotide triphosphates (dNTPs) in a single reaction mixture. This modification degraded unincorporated dNTPs and ATP after each addition, preventing carryover and improving the efficiency and accuracy of real-time sequencing by allowing sequential incorporation without the need for separate washes. Building on this foundation, 2005 marked the launch of the 454 Sequencing platform by 454 Life Sciences, which adapted pyrosequencing for using picotiter plates containing millions of microwells. This innovation facilitated simultaneous sequencing of up to 200,000 DNA fragments, achieving read lengths of about 100 bases and dramatically increasing throughput compared to earlier serial methods. A key component of this high-throughput variant was the integration of emulsion PCR for clonal amplification, where DNA fragments were immobilized on beads within water-in-oil emulsions to generate millions of identical copies per bead, enabling scalable signal detection in the picotiter plate format. By 2013, the 454 platform faced obsolescence amid competition from faster next-generation sequencing methods with longer reads and lower costs, leading — which had acquired 454 Life Sciences in 2007—to discontinue the technology and close the . This shift highlighted pyrosequencing's evolution from a pioneering real-time method to a foundational influence on broader NGS landscapes, though its specific implementations waned in favor of more versatile alternatives.

Principles

Biochemical Mechanism

Pyrosequencing operates on the principle of sequencing by synthesis, where a single-stranded DNA template is hybridized to a sequencing primer, and DNA polymerase extends the primer by incorporating complementary deoxyribonucleotide triphosphates (dNTPs) in a template-directed manner. Each incorporation event releases one molecule of pyrophosphate (PPi) per nucleotide added, with the amount of PPi produced being directly proportional to the number of nucleotides incorporated in a given cycle. Typically, an exonuclease-deficient Klenow fragment of Escherichia coli DNA polymerase I is employed to ensure processive synthesis without degrading the newly formed strand. The released PPi is then enzymatically converted to adenosine triphosphate (ATP) by ATP sulfurylase in the presence of adenosine 5'-phosphosulfate (APS), a reaction that occurs rapidly within approximately 1.5 seconds. This ATP fuels the subsequent oxidation of D-luciferin by , producing oxyluciferin and generating a burst of visible light () at around 560 nm, with the light intensity proportional to the ATP concentration and thus to the number of incorporated . The bioluminescent signal is detectable in real time, enabling immediate readout of the synthesis events without the need for labeled . To prevent carryover from unincorporated dNTPs or residual ATP that could interfere with subsequent cycles, apyrase—a diphosphohydrolase—is used to hydrolyze these molecules into monophosphates and inorganic , effectively resetting the reaction environment. In the liquid-phase format of pyrosequencing, apyrase allows for a continuous, wash-free process, while solid-phase variants may incorporate washing steps. are added sequentially (A, T, C, G) in a controlled manner, with the enzyme mixture refreshed as needed to maintain activity. A key limitation in the biochemical mechanism arises during homopolymeric stretches, where multiple identical are incorporated in a single addition cycle, resulting in a cumulative PPi release and correspondingly stronger light signal. However, the light intensity does not scale linearly beyond five to six consecutive due to saturation and other kinetic factors, making precise quantification of longer homopolymers challenging and often requiring software corrections or modified addition strategies.

Detection and Signal Generation

In pyrosequencing, the release of (PPi) during triggers an enzymatic cascade that generates a detectable signal. This signal arises from the conversion of PPi to (ATP) by ATP sulfurylase, followed by the oxidation of to oxyluciferin by in the presence of ATP, producing visible in proportion to the amount of PPi released. The emission is captured using sensitive optical detectors, primarily a (CCD) camera in modern implementations, which images the bioluminescent reaction across multiple reaction sites in a microtiter plate format. Earlier systems employed photomultiplier tubes or arrays for single-well detection via luminometry, enabling real-time monitoring of the reaction. The intensity of the emitted light is directly proportional to the quantity of PPi produced, which in turn corresponds to the number of nucleotides incorporated by the during each dispensing cycle. This results in a characteristic pyrogram, where each addition produces a distinct peak, and the peak height reflects the length of homopolymeric stretches—for instance, incorporation of two identical bases yields a peak approximately twice as high as one for a single base. However, proportionality holds accurately only for short homopolymers (up to 5–6 bases), as longer stretches introduce nonlinearity due to and substrate limitations. Raw light signals are processed by software algorithms that integrate peak areas to quantify incorporation events and perform base calling by matching observed patterns to the expected sequence of nucleotide dispensations. These algorithms, such as those in the original PSQ systems, apply thresholds and normalization to distinguish true signals from background noise, enabling accurate decoding of the DNA sequence. In early assays, calibration for absolute PPi quantification relied on enzyme luminometry, where standard curves were generated by measuring light output from known PPi concentrations to ensure quantitative accuracy across the attomole to picomole range.

Procedure

Sample Preparation and Setup

Sample preparation for pyrosequencing begins with the (PCR) amplification of the target region, utilizing one biotinylated primer paired with a standard non-biotinylated primer to generate double-stranded amplicons where one strand is labeled with biotin. This biotinylation facilitates subsequent strand separation and immobilization, ensuring the production of sufficient template material, typically from 10 ng of input genomic in a 50 µl reaction volume under standard cycling conditions (e.g., 94°C for 2 min, followed by 32 cycles of 94°C for 40 s, 56°C for 45 s, and 72°C for 45 s, with a final extension at 72°C for 10 min). Following PCR, the biotinylated double-stranded amplicons are immobilized by binding to streptavidin-coated magnetic beads, typically using 5-20 µl of the PCR product mixed with 2.5-3.5 µl of bead suspension and agitated for at least 5 minutes to allow efficient capture. The non-biotinylated strand is then removed through denaturation, achieved by sequential washes with 70% , 0.2 M , and a neutralization buffer (0.1 M Tris-acetate, 7.6) using a filtration tool or to isolate the single-stranded biotinylated template. This step yields a purified single-stranded DNA template bound to the beads, ready for primer annealing. The sequencing primer, specific to the region upstream of the target , is then annealed to the immobilized single-stranded template by resuspending the beads in annealing buffer and incubating at 80-90°C for 2 minutes, followed by cooling to 60°C for 7-10 minutes and then to for 5 minutes, using 4-8 pmol of primer per reaction. Optimization of template quantity is critical to prevent signal saturation or weak detection; protocols recommend 0.5-2 pmol of single-stranded template per well to balance sensitivity and dynamic range during the subsequent enzymatic reactions. This preparation ensures the template is optimally configured for the real-time sequencing-by-synthesis process without interference from excess or insufficient material.

Sequencing Execution and Data Acquisition

The sequencing execution in pyrosequencing begins with the addition of the enzyme mixture, which includes , ATP sulfurylase, , and apyrase, to the reaction wells containing the immobilized single-stranded DNA template and annealed sequencing primer. Deoxynucleotide triphosphates (dNTPs) are then dispensed cyclically, one type at a time (dATPαS, dCTP, dGTP, dTTP), in a predetermined order optimized for the target sequence to minimize asynchronous synthesis. The dATPαS analog replaces natural dATP to prevent inhibition of the enzyme while maintaining efficient incorporation by the . Upon dispensation, if the dNTP is complementary to the template, it is incorporated, releasing that triggers the enzymatic cascade to produce a proportional light signal; unincorporated dNTPs are degraded by apyrase. Following each dispensation, a washing step removes residual reagents and unincorporated from the solid-phase reaction chamber to prepare for the next cycle, ensuring signal specificity. emission is monitored in real-time using a charge-coupled device (CCD) camera or , capturing the bioluminescent signal at 560 nm after each addition, with the intensity reflecting the number of consecutive incorporations (e.g., higher peaks for homopolymers). This process repeats for hundreds of cycles, typically yielding reads of up to 400 base pairs in optimized conditions. The raw data are compiled into a pyrogram, a graphical representation plotting light intensity peaks against the dispensation order, where the sequence is inferred from peak presence and height corresponding to each addition. Benchtop instruments like the PyroMark Q24 or the now-discontinued PSQ 96 (support ended August 2025) enable parallel processing of up to 96 samples per run, with typical execution times of 1–2 hours for full sequencing reactions depending on read length and dispensation complexity. Post-run quality control involves analyzing pyrogram baselines for noise, peak symmetry, and signal decay, often using built-in software to verify activity through parallel control reactions with known synthetic templates or enzyme mix validations. These controls confirm consistent and performance, flagging issues like incomplete dNTP degradation or template misalignment for .

Applications

Research and Genomic Analysis

Pyrosequencing has significantly advanced research in genomics by enabling the de novo sequencing of small genomes in its early applications, prior to the widespread adoption of shorter-read next-generation sequencing (NGS) technologies. A landmark achievement occurred in 2005 when researchers utilized the 454 pyrosequencing platform to assemble the complete 580 kb genome of Mycoplasma genitalium from scratch, generating over 300,000 high-quality reads averaging 110 bases in length with 40-fold coverage, resulting in 25 contigs and 99.994% consensus accuracy. This was accomplished through DNA fragmentation, adapter ligation, emulsion PCR amplification in picolitre reactors, and real-time pyrosequencing over 42 cycles, demonstrating a 10-fold increase in throughput compared to Sanger sequencing while reducing costs and time for bacterial genome projects. The success highlighted pyrosequencing's suitability for targeted, high-coverage sequencing of compact genomes, influencing subsequent metagenomic and population-level studies. In , pyrosequencing facilitates high-throughput (SNP) genotyping and mutation detection, allowing researchers to screen large cohorts efficiently. By sequencing short regions flanking SNPs, the method produces distinct pyrophosphate-dependent light signals for each , enabling real-time quantification with software-based . Automated systems process up to 96 samples within 10 to 20 minutes, supporting estimation and association analyses in diverse populations. For instance, optimized dispensing orders ensure accurate variant calling, making it ideal for evolutionary studies and identifying rare mutations across thousands of individuals. For epigenetic investigations, pyrosequencing provides quantitative analysis of patterns from bisulfite-treated templates, offering site-specific resolution critical for regulatory research. Bisulfite conversion alters unmethylated cytosines to uracil (read as ), while methylated cytosines remain unchanged; pyrosequencing then measures the cytosine-to- ratio at each via sequential incorporation. Methods like Pyro Q-CpG enable profiling of multiple consecutive sites, such as the seven CpG dinucleotides in the p16^INK4A promoter, yielding reproducible methylation percentages that reveal heterogeneous patterns in control. Pyrosequencing supports metagenomic research through 16S rRNA amplicon sequencing for microbial community profiling, capturing bacterial diversity in complex samples. Targeting hypervariable regions (V1–V9) of the 16S rRNA gene via PCR, followed by pyrosequencing on platforms like 454, generates 300,000–400,000 reads per run, identifying taxa at 95–97% sequence identity thresholds using databases such as RDP and Greengenes. This approach has elucidated community structures in environments like the human gut, detecting overlooked by culture-based or low-throughput methods. Owing to its precision in low-complexity, short sequences, pyrosequencing serves as a gold standard for validating NGS results in targeted regions, particularly for SNPs. In natural population studies, it has corroborated pooled NGS-derived allele frequencies with high fidelity, showing correlations exceeding R² = 0.97 and average differences under 4% across loci, without systematic bias even at 55–284× coverage. This validation confirms NGS accuracy for specific amplicons, enhancing confidence in downstream genomic interpretations.

Clinical and Forensic Uses

Pyrosequencing has emerged as a valuable tool in clinical diagnostics for detecting pharmacogenetic variants that influence and response, particularly in . For instance, it enables accurate determination of gene copy number variations, which are critical for predicting phenotypes such as poor, intermediate, extensive, or ultrarapid metabolizers of drugs like and antidepressants. This method offers high reproducibility and sensitivity, allowing of alleles associated with adverse drug reactions or therapeutic efficacy in psychiatric and settings. In infectious disease diagnostics, pyrosequencing facilitates rapid pathogen identification and profiling of mutations, aiding timely treatment decisions. It has been applied to detect clarithromycin resistance-associated point mutations in , a common cause of gastric ulcers and cancer, with a detection limit suitable for clinical samples and results obtainable within hours. Similarly, the technique identifies virulence genes and resistance markers in pathogens like , supporting preparedness and outbreak management through unambiguous strain differentiation. Forensic applications of pyrosequencing include analysis of short tandem repeats (STRs) for , particularly in challenging samples. The method supports autosomal and Y-chromosomal STR typing, enabling resolution of mixtures from multiple contributors in or mass disaster cases by quantifying peak heights and distinguishing minor components at low DNA input levels. Its sequence-based readout provides enhanced discrimination power over traditional , improving accuracy in kinship and paternity testing. In , pyrosequencing assesses somatic mutations in tumor biopsies to guide targeted therapies, contributing to evaluations of tumor mutation burden (TMB) as a for response. It detects low-frequency mutations in genes like EGFR and in non-small cell lung cancer and specimens, with sensitivity down to 5% mutant alleles, informing decisions on inhibitors such as or . For BRAF mutations in , the assay quantifies variant allele frequencies to stratify patients for therapy, highlighting intratumoral heterogeneity that impacts treatment outcomes. Regulatory approvals underscore pyrosequencing's role in validated clinical assays, including those for DNA methylation analysis in colorectal cancer screening. Pyrosequencing-based quantification of promoter methylation, such as in the LINC00473 gene in tissue samples, has shown promise for colorectal tumor detection, with high specificity in distinguishing malignant from benign cases. This approach supports the development of methylation biomarkers, such as the FDA-cleared SEPT9 assay, which achieves early detection sensitivity of around 70% for colorectal cancer using PCR-based methods in blood-based tests. As of 2024, compact platforms like the Pyromark Q48 have been validated for routine clinical use in targeted mutation detection.

Limitations and Challenges

Technical Drawbacks

One significant technical limitation of pyrosequencing is its reduced accuracy in resolving homopolymeric regions, where multiple consecutive identical nucleotides are present. The method relies on detecting the intensity of light emitted proportionally to the number of incorporated nucleotides during synthesis, but this response becomes non-linear for homopolymers longer than approximately 6-8 bases, leading to under- or overestimation of the repeat length. This issue arises because the enzymatic cascade and light detection system do not scale linearly with incorporation events beyond short stretches, resulting in signal saturation or noise that complicates precise base calling. Read lengths in pyrosequencing are typically constrained to 300-500 base pairs, which limits its utility for applications requiring extensive contiguous sequence data, such as de novo genome assembly. This restriction stems primarily from the progressive desynchronization of DNA extension across multiple template molecules in the reaction, where incomplete or uneven incorporations accumulate over successive flows, degrading signal quality and alignment accuracy. As a result, longer sequences become unreliable, necessitating shorter amplicons and multiple overlapping runs for broader coverage. The polymerase employed in pyrosequencing, often the of , lacks 3'-5' activity, contributing to incorporation errors during synthesis with an overall sequencing error rate of approximately 1%. This limitation, combined with the real-time nature of the , allows mismatches, insertions, and deletions—particularly in homopolymeric regions—to propagate without correction, elevating the raw error profile compared to methods using enzymes. While post-processing can mitigate some discrepancies, the inherent enzymatic constraints affect base-calling precision, especially in error-prone templates. Pyrosequencing exhibits sensitivity to secondary structures in the DNA template, such as hairpins or folds in GC-rich regions, which can impede polymerase progression and cause incomplete extensions. These structures hinder the annealing and extension of the sequencing primer or lead to pausing during nucleotide addition, resulting in signal gaps or desynchronized flows that truncate reads prematurely. Strategies like adding single-stranded DNA-binding proteins have been explored to stabilize templates and reduce such artifacts, but the method remains vulnerable without optimized conditions. Effective pyrosequencing requires prior knowledge of flanking sequences adjacent to the target region for designing specific annealing primers, as the method initiates synthesis from a defined primer-template hybrid. Without this , primer placement is challenging, limiting de novo applications and necessitating reference-based design for targeted regions like SNPs or short amplicons. This dependency on known contexts restricts flexibility in exploratory sequencing workflows.

Practical and Economic Constraints

One of the main economic barriers to widespread adoption of pyrosequencing is the high cost of reagents, stemming from the need for specialized enzyme mixes—including , ATP sulfurylase, , and apyrase—and single-use cartridges or reaction kits for each sequencing run. For example, reagent and processing costs for pyrosequencing assays typically range from $4 to $17 per sample, depending on the platform and volume, which can accumulate significantly for multi-locus analyses. These expenses are driven by the formulations optimized for the sequencing-by-synthesis chemistry, making pyrosequencing less cost-effective for high-volume applications compared to some alternative methods. Practical implementation of pyrosequencing is hindered by its labor-intensive setup, particularly in low-throughput benchtop systems like the former PyroMark, where manual steps for , primer annealing, and cartridge loading limit scalability and increase hands-on time per run. The technique's reliance on precise pipetting and checks further exacerbates this, often requiring 1-2 hours of preparation for small batches, which constrains its use in resource-limited labs. Interpreting pyrograms— the graphical output showing light emission peaks—and troubleshooting issues like signal noise or incomplete extensions demands specialized training, as users must understand nucleotide dispensation orders and peak quantification to avoid misinterpretation. This educational requirement, combined with the need for familiarity with software analysis tools, can pose a steep for new operators and contribute to variability in results across labs. The enzymatic components of pyrosequencing are highly sensitive to environmental factors, necessitating controlled conditions such as stable temperatures around 28°C, consistent , and minimal contamination to prevent denaturation or reduced activity. Deviations in these parameters can lead to inconsistent signals and failed runs, thus requiring dedicated climate-controlled spaces and regular instrument maintenance. Following Roche's discontinuation of the 454 pyrosequencing platform in 2013, with production ceasing by mid-2016, and QIAGEN's phase-out of several PyroMark models—with support for the Q96 ID ending on August 31, 2025, and for the Q24 until the end of 2026—support for pyrosequencing systems has significantly declined, including limited availability of replacement parts, reagents, and technical assistance, complicating maintenance and long-term use.

Comparisons

Versus Sanger Sequencing

Pyrosequencing employs a real-time sequencing-by-synthesis approach, where the release of during incorporation is detected via in a cascade reaction involving enzymes such as , ATP sulfurylase, and , allowing for immediate signal generation without physical separation of products. In contrast, relies on chain-termination with dideoxynucleotides, followed by electrophoretic separation of labeled fragments on gels or capillaries to determine sequence order based on fragment sizes. This fundamental difference enables pyrosequencing to perform parallel processing in multi-well formats, such as the PSQ96 system that sequences up to 96 samples simultaneously in 40-50 minutes for short stretches, providing higher throughput for targeted analyses. While pyrosequencing excels in generating short reads of approximately 100 bases, it is limited to predetermined regions, making it suitable for focused applications but less ideal for extensive de novo sequencing. , however, produces longer reads of 800-1000 base pairs with high fidelity, supporting its role as the gold standard for accurate, clone-by-clone validation of sequences like inserts. Pyrosequencing offers cost efficiency for such targeted resequencing, with lower reagent expenses and reduced labor compared to Sanger's more intensive preparation and analysis, particularly for short amplicons where overall costs are considerably lower. Pyrosequencing requires prior PCR amplification to generate sufficient single-stranded template DNA bound to a known primer site, limiting its use for unknown sequences without targeted enrichment. Sanger sequencing demonstrates greater versatility in this regard, as it can directly sequence diverse templates such as uncloned inserts or genomic fragments using universal primers, accommodating a broader range of unknowns. Additionally, pyrosequencing faces challenges in accurately resolving homopolymer stretches longer than 5-6 bases due to proportional light signals, an issue less pronounced in Sanger's fragment-based resolution.

Versus Next-Generation Sequencing Technologies

Pyrosequencing distinguishes itself from other next-generation sequencing (NGS) technologies through its enzyme-based detection mechanism, which relies on the real-time of release during . In this process, unincorporated is converted to ATP by ATP sulfurylase, which then drives a reaction producing visible light proportional to the number of incorporated ; this light is captured via a camera. In contrast, dominant NGS platforms like Illumina employ fluorescence-based detection of reversible terminator nucleotides, allowing for cyclic imaging of millions to billions of clusters per run, while Ion Torrent platforms detect shifts from proton release without optical components. These differences enable NGS to achieve sequencing of billions of short reads (typically 50–300 ), far exceeding the output of historical high-throughput pyrosequencing platforms like 454, which produced up to several million reads per run with longer reads (200–1,000 ) before being discontinued around 2016. Current pyrosequencing systems focus on targeted, low-throughput applications with short reads of ~100 . For targeted sequencing applications, pyrosequencing often provides a lower per base compared to comprehensive NGS workflows, particularly when analyzing small genomic regions or amplicons, due to its simpler setup and reduced need for extensive library preparation and bioinformatics. Historical data from early 454 pyrosequencing indicated relatively low costs for targeted panels, making it economical for validation of specific variants without the overhead of whole-genome coverage. Conversely, NGS platforms like Illumina excel in cost-efficiency for large-scale projects, with 2025 estimates placing whole-genome sequencing below $600 per sample (or ~$0.0002 per megabase) through high-throughput , though targeted NGS panels can approach $100–500 per sample for smaller cohorts. This positions pyrosequencing as more suitable for low-to-medium throughput needs, avoiding the amortization of high instrument costs over vast data volumes required by NGS. Pyrosequencing demonstrates superior accuracy for short homopolymeric stretches (up to 4 ), where its light intensity signal reliably distinguishes incorporation lengths, achieving rates below 1% in these regions. However, accuracy declines for longer homopolymers due to non-linear signal response. In comparison, NGS technologies like Illumina generally offer higher overall per-base accuracy (99.9% or better) and are robust in homopolymeric regions with low rates (~1% or less), though platforms like Ion Torrent exhibit higher in such areas without unique molecular identifiers (UMIs) to correct amplification biases and . The incorporation of UMIs in modern NGS workflows has mitigated these issues, enhancing reliability in complex genomes. Despite NGS's dominance in de novo genome assembly and large-scale —driven by platforms like Illumina's NovaSeq series capable of terabase-scale output—pyrosequencing persists in niche roles for variant validation and epigenetic analysis, where its real-time, quantitative readout provides confirmatory precision without the computational burden of short-read assembly. As of 2025, pyrosequencing serves primarily as a complementary tool rather than a direct competitor to NGS's , with its market focused on specialized kits for clinical validation and modest growth in targeted applications. While high-throughput implementations like 454 are discontinued, the technology endures in benchtop systems for precise, short-read analysis.

Commercialization

Early Commercialization Efforts

Pyrosequencing AB was established in 1997 in Uppsala, Sweden, by a team of Swedish inventors including Pål Nyrén, Mostafa Ronaghi, Mathias Uhlén, Bertil Pettersson, and Björn Ekström, with initial funding from venture capital firm HealthCap to develop and commercialize instruments based on the pyrosequencing DNA sequencing method. The company focused on automating the technology for practical applications in genomics, marking the transition from academic research to industrial production of sequencing tools. In 2000, Pyrosequencing AB launched the PSQ 96 system, an automated 96-well plate platform designed primarily for low-throughput (SNP) analysis, enabling parallel processing of multiple samples for targeted detection. This instrument represented the first commercial product from the company, targeting research labs needing efficient genotyping solutions without the need for . By 2003, amid expanding operations, Pyrosequencing AB acquired U.S.-based Biotage LLC and Swedish firm Personal Chemistry i AB, after which it restructured and renamed itself Biotage AB to reflect its broadened portfolio in life sciences tools. A pivotal development occurred in August 2003 when Pyrosequencing AB granted an exclusive for its to 454 Life Sciences for whole-genome sequencing applications, while retaining rights for SNP and short-read uses. This partnership facilitated the 2005 release of the 454 GS 20 instrument, the first commercial next-generation sequencer, which generated up to 200,000 reads per run and supported de novo genome assembly, exemplified by the complete sequencing of the bacterial genome of Mycoplasma genitalium in a single four-hour run and early efforts in viral genome sequencing. In March 2007, Diagnostics acquired 454 Life Sciences for up to $154.9 million, including $140 million in cash and $14.9 million in contingent payments, integrating the into its portfolio and accelerating advancements. Under , the platform evolved further with the 2008 launch of the GS FLX upgrade, capable of producing approximately 1 million reads per run with read lengths up to 400-600 base pairs, significantly boosting throughput for large-scale genomic projects. These efforts positioned pyrosequencing at the forefront of the sequencing market during the mid-2000s, with rapid adoption in academic and pharmaceutical research driven by its speed and automation advantages over . However, by the late 2000s, intensifying competition from emerging next-generation sequencing platforms offering higher throughput and lower costs began to erode its market dominance.

Current Status and Providers

As of 2025, QIAGEN remains the primary provider of pyrosequencing technology, having acquired the relevant assets from Biotage AB's Biosystems division for up to $53 million in 2008, which encompassed the core pyrosequencing intellectual property and instrumentation. This acquisition enabled QIAGEN to develop and sustain the PyroMark series, including the actively supported PyroMark Q48 Autoprep system, optimized for targeted sequencing assays such as quantitative methylation analysis in epigenetics. However, QIAGEN discontinued support for legacy platforms like the PyroMark Q96 ID on August 31, 2025, with production of reagents ceasing at that time; existing stock remains available while supplies last to encourage migration to newer automated workflows. Pyrosequencing holds a niche position in the 2025 sequencing landscape, with primary applications in for precise CpG quantification and in forensics for DNA-based age estimation and identification through epigenetic markers. Annual sales of QIAGEN's PyroMark consumables and maintenance services sustain a specialized user base in academic and clinical labs focused on these areas, though broader adoption has waned due to competition from scalable NGS platforms. Roche's discontinuation of the high-throughput 454 pyrosequencing system in marked a pivotal shift, as the company ceased production of the GS FLX and Junior instruments, redirecting pyrosequencing's role toward low-throughput validation of NGS results in targeted genetic and epigenetic studies. Recent advancements integrate pyrosequencing with workflows for verifying editing outcomes, particularly in epigenetic modifications where it quantifies site-specific changes induced by dCas9 fusion proteins. Similarly, adaptations for single-cell pyrosequencing enable heteroplasmy detection in , supporting applications in mitochondrial disorders and forensic trace analysis. Market projections for pyrosequencing suggest stable but marginal growth through 2030, confined to validation niches and overshadowed by long-read NGS technologies like PacBio's HiFi sequencing, which offer higher throughput and accuracy for complex genomic regions.

References

  1. https://doi.org/10.1126/science.281.5375.363
  2. https://doi.org/10.1101/gr.11.1.3
  3. https://doi.org/10.1006/abio.1993.1024
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC3116506/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC9088475/
  6. https://pubmed.ncbi.nlm.nih.gov/8382019/
  7. https://pubmed.ncbi.nlm.nih.gov/17185753/
  8. https://pubmed.ncbi.nlm.nih.gov/8923969/
  9. https://www.nature.com/articles/nature03959
  10. https://www.genomeweb.com/sequencing/roche-shutting-down-454-sequencing-business
  11. https://www.science.org/doi/10.1126/science.281.5375.363
  12. https://genome.cshlp.org/content/11/1/3.full
  13. https://meridian.allenpress.com/aplm/article/137/9/1296/193658/Fundamentals-of-Pyrosequencing
  14. https://doi.org/10.1038/nprot.2007.244
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2933062/
  16. https://www.qiagen.com/us/resources/faq/3721
  17. https://www.qiagen.com/us/resources/download.aspx?id=98ca0eca-309e-460b-b819-d0b1ca036f9c&lang=en
  18. https://www.qiagen.com/fr/resources/download.aspx?id=1ff93ed3-6c1f-4e90-af43-8cce702bbcc1&lang=en
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC310924/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC10324197/
  21. https://www.sciencedirect.com/science/article/abs/pii/S016770121200190X
  22. https://pubmed.ncbi.nlm.nih.gov/20129471/
  23. https://www.sciencedirect.com/science/article/abs/pii/S187249730800183X
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC3120717/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC1975103/
  26. https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-022-01302-x
  27. https://www.mdpi.com/2075-4418/15/3/390
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC9895957/
  29. https://academic.oup.com/bioinformatics/article/29/16/1963/203896
  30. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061762
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC1978072/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC3655449/
  33. https://www.tandfonline.com/doi/full/10.2144/04371ST02
  34. https://grcf.jhmi.edu/service/pyrosequencing/
  35. https://www.qiagen.com/us/resources/download.aspx?id=1ff93ed3-6c1f-4e90-af43-8cce702bbcc1&lang=en
  36. https://www.qiagen.com/us/products/discovery-and-translational-research/pyrosequencing/pyromark-q24-and-advanced
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC2932963/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC2893626/
  39. https://thescipub.com/pdf/ajbbsp.2012.14.20.pdf
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC10246072/
  41. https://www.completegenomics.com/next-generation-sequencing-costs/
  42. https://www.illumina.com/science/technology/next-generation-sequencing/beginners/ngs-cost.html
  43. https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-018-4544-x
  44. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.982111/full
  45. https://www.datainsightsmarket.com/reports/pyrosequencing-1980143
  46. https://www.biotage.com/biotage-history
  47. https://www.researchgate.net/publication/6614197_The_History_of_PyrosequencingR
  48. https://news.cision.com/pyrosequencing/r/second-quarter-results%2Ce27569
  49. https://www.globenewswire.com/news-release/2003/08/19/299748/1032/en/454-Life-Sciences-obtains-license-from-Pyrosequencing.html
  50. https://www.nature.com/articles/nbt1105-1333
  51. https://www.genengnews.com/news/roche-buys-454-for-154-9m/
  52. https://www.crg.eu/en/content/454-sequencing
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC2347365/
  54. https://www.genengnews.com/news/qiagen-buys-biotages-biosystems-segment-and-shares-in-corbett-for-53m/
  55. https://www.genomeweb.com/sequencing/qiagen-acquires-biotage-pyrosequencing-tech-mdx-applications
  56. https://www.qiagen.com/an/resources/download.aspx?id=1ff93ed3-6c1f-4e90-af43-8cce702bbcc1&lang=en
  57. https://onlinelibrary.wiley.com/doi/10.1002/elps.202200177
  58. https://pubmed.ncbi.nlm.nih.gov/36168852/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC8378768/
  60. https://www.nature.com/articles/gt201582
  61. https://pubmed.ncbi.nlm.nih.gov/24803323/
  62. https://link.springer.com/protocol/10.1007/978-1-4939-3308-2_34
  63. https://www.fortunebusinessinsights.com/industry-reports/pyrosequencing-market-100327
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.